Compare SEAT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEAT | OMER |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 844.6M |
| IPO Year | 2021 | 2008 |
| Metric | SEAT | OMER |
|---|---|---|
| Price | $6.27 | $19.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $18.06 | ★ $32.50 |
| AVG Volume (30 Days) | 46.3K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.60 | $233.22 |
| P/E Ratio | ★ N/A | $23.66 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.06 | $3.94 |
| 52 Week High | $18.73 | $19.65 |
| Indicator | SEAT | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 77.10 |
| Support Level | $6.13 | $9.12 |
| Resistance Level | $7.69 | N/A |
| Average True Range (ATR) | 0.46 | 0.94 |
| MACD | -0.08 | 0.21 |
| Stochastic Oscillator | 3.85 | 96.85 |
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry, providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada, and Japan. It operates in two segments: Marketplace, which generates maximum revenue, and Resale. The Marketplace segment acts as an intermediary between ticket buyers, sellers, and partners, earning revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. The Resale segment acquires tickets to resell on secondary ticket marketplaces, including its own, and offers internal research and development support for Skybox.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.